Funding opportunities
Below is a list of funding opportunities that may be relevant for thoracic cancer research, including basic scientific research. Please read the funding guidelines to determine if your research proposal is eligible and that you meet other eligibility requirements.
Any TOGA member can apply for TOGA endorsement of their thoracic cancer research proposal, taking advantage of peer- and consumer-review by TOGA working groups in the following areas:
- Early non small cell lung cancer
- Advanced non small cell lung cancer
- Small cell lung cancer/mesothelioma
- Supportive and palliative care
- Translational research
TOGA endorsement offers the following benefits:
- Use of TOGA logo or TOGA acknowledgment on all applications, presentations and publications
- Membership mailouts to assist with recruitment
- Listing of trial on the TOGA website
- Updates presented at Scientific Committee or other TOGA meetings (time permitting)
Further information is available in the TOGA Endorsement Policy.
The next deadline for submission of concepts for peer- and consumer review and application for endorsement will be posted on social media and circulated in a members’ newsletter. Send concepts at any time to info@thoraciconcology.org.au
If you know of additional funding opportunities that we can list, please contact info@thoraciconcology.org.au
| Grant Name | Research funded | Grant open date | Close date | Max funding | Duration | Application requirements |
|---|---|---|---|---|---|---|
| WA Cancer Council Cancer Research Project Grants | Aboriginal health; rural and remote health; clinical health; and public health | May 15, 2024 | Expression of interest: June 26, 2024 Full application (on request) October 8, 2024 | $140K | 1 year | CIA must hold a primary appointment at a Higher Education and/or Medical Research Institute in WA. Early and mid career researchers strongly encouraged as CIs. More Info |
| FY24 Lung Cancer Research Program - Patient-Centered Outcomes and Survivorship Award | Supports high-reward studies that span the spectrum of behavioural health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, comorbid conditions and examining the physical, psychological, social, and economic effects of lung cancer. | March 28, 2024 | Pre-Application (Letter of Intent): July 17, 2024 5:00 p.m. ET Application: August 7, 2024 11:59 p.m. ET | $650K | 3 years | Applications must be submitted via eBRAP |
| GO6578 – 2023 Innovative Trials National Critical Research Infrastructure Initiative | Various opportunities examining: -feasibility of national adaptive platform trials -establishment or expansion of a national adaptive trial in an area of unmet need -Conduct a registry-randomised trial in an area of unmet need -Evidence of efficiency/cost effectiveness of registry randomised trials or adaptive trial platforms over conventional trial designs | 6 February 2024 | 10-Jul-2024 5:00 pm (ACT Local Time) | Up to $5 million | 2 years | complete the online program application form |
| US dept of Defense Grants in Lung cancer: Patient-Centered Outcomes and Survivorship Award (PCOSA) | Supports high-reward studies that span the spectrum of behavioral health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, comorbid conditions and examining the physical, psychological, social, and economic effects of lung cancer. • Must address at least one area of emphasis in the Disparities or Health Outcomes/Survivorship categories. | Currently open | Pre-Application (Letter of Intent): July 17, 2024 5:00 p.m. Eastern time Application: August 7, 2024 11:59 p.m. Eastern time | USD$650,000 | 3 years | General application instructions |
| GO7022-NHMRC Clinical Trials and Cohort Studies Grants | High-quality clinical trials that provide reliable evidence of the effects of health-related interventions on health outcomes (or appropriate surrogates). High-quality cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes. High quality retrospective cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes. | Currently open | Min data 24 July 2024 Full applications close 28 Aug 2024 | The provisional funding allocation for the entire Clinical Trials and Cohort Studies Grants 2024 is $70 million. Individual grant amounts are not specified | 1-5 years | Sapphire Applications will only be accepted from NHMRC approved Administering Institutions |
| GO6361 NHMRC-EU Collaborative Research Grant Scheme 2024 | Projects involving Australian-based researchers chosen by the EU for funding may be eligible for NHMRC support. NHMRC is considering supporting Australian researchers for Horizon Europe submitted through the two-stage deadline model. | 12 July 2023 Currently open | 16 October 2024 (17:00 ACT time) | $1 Million | 5 years | Application form submitted through Sapphire |
| MRFF - 2024 International Clinical Trial Collaborations Grant Opportunity | Australian involvement in international collaborative investigator-initiated clinical trials research through the establishment and co-ordination of clinical trial site/s in Australia. | 6 March 2024 | Round 1- Min data due 3 July 2024; Full application due 31 July 2024 Round 2- Min data due 4 Dec 2024; Full application due 5 Feb 2025 | $3 million | 5 years | Applicants are advised to read the Grant Guidelines. Applications must be submitted using Sapphire, the NHMRC's grant system. |
